文献速递乳腺乳腺X线MR

对比增强乳腺X线摄影与MRI评估乳腺癌新辅助治疗反应的前瞻性研究

Contrast-Enhanced Mammography Versus MRI in the Evaluation of Neoadjuvant Therapy Response in Patients With Breast Cancer: A Prospective Study.
PubMed 文献 · AJR Am J Roentgenol · 2022-06-22

前瞻性纳入51例拟行新辅助治疗的乳腺癌患者,于治疗前、中、后分别行对比增强乳腺X线摄影(CEM)与MRI。CEM与MRI的病灶大小测量及RECIST反应分类一致性良好;MRI检测病理完全缓解的敏感度高于CEM,特异度无显著差异;延迟CEM采集可能有助于检出残留导管原位癌。

要点

  • CEM与MRI的RECIST反应分类一致性良好:治疗中kappa=0.791,治疗后kappa=0.871。
  • 治疗后MRI检测病理完全缓解的敏感度100%,高于CEM的81%(p=.001)和延迟CEM的81%(p=.002)。
  • 治疗后CEM、MRI及延迟CEM测得的病灶大小均较病理偏大,平均差值分别为0.8 mm、1.2 mm和1.9 mm。

核心结论

  • 新辅助治疗后,CEM与MRI对病灶大小和RECIST分类的评估相当,两者均较病理轻度高估;检测病理完全缓解的特异度无显著差异,MRI敏感度更高;延迟CEM采集可能有助于检出残留导管原位癌。

研究设计与样本

  • 前瞻性研究,纳入2015年5月至2018年4月间51例经活检证实、拟行新辅助治疗的乳腺癌患者(平均年龄46±11岁),于治疗前、治疗中和治疗后均行CEM和MRI检查,治疗后CEM包含6分钟延迟采集;由一名有CEM经验的乳腺放射科医师阅CEM、一名有MRI经验的乳腺放射科医师阅MRI;以病理为参考,病理完全缓解定义为浸润性癌和导管原位癌均缺失。

关键影像表现/征象

  • 治疗后12例残留导管原位癌患者中,治疗后CEM检出强化病灶7例,治疗后MRI检出8例,治疗后延迟CEM检出9例。

诊断标准与关键数值

  • 治疗后影像检测病理完全缓解:CEM敏感度81%、特异度83%;MRI敏感度100%、特异度86%;延迟CEM敏感度81%、特异度89%。
  • MRI检测病理完全缓解的敏感度显著高于CEM(p=.001)和延迟CEM(p=.002),其余比较均无显著差异(p>.05)。
  • CEM与MRI的RECIST反应分类一致性kappa系数:治疗中0.791,治疗后0.871。
  • CEM较MRI测得的病灶大小系统性偏小:治疗前平均差-0.2 mm,治疗中-0.7 mm,治疗后-0.3 mm。
  • 治疗后影像较病理测得的病灶大小系统性偏大:CEM平均差0.8 mm,MRI平均差1.2 mm,延迟CEM平均差1.9 mm。

临床应用与阅片要点

  • 原文结论指出,尽管MRI仍是新辅助治疗反应监测的首选检查,但研究结果支持在MRI禁忌或不耐受时,CEM可作为有用的替代选择。
  • 治疗后延迟CEM采集可能有助于检出残留导管原位癌。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND. Contrast-enhanced mammography (CEM) is rapidly expanding as a credible alternative to MRI in various clinical settings. OBJECTIVE. The purpose of this study was to compare CEM and MRI for neoadjuvant therapy (NAT) response assessment in patients with breast cancer. METHODS. This prospective study included 51 patients (mean age, 46 ± 11 [SD] years) with biopsy-proven breast cancer who were candidates for NAT from May 2015 to April 2018. Patients underwent both CEM and MRI before, during, and after NAT (pre-NAT, mid-NAT, and post-NAT, respectively). Post-NAT CEM included a 6-minute delayed acquisition. One breast radiologist with experience in CEM reviewed CEM examinations; one breast radiologist with experience in MRI reviewed MRI examinations. The radiologists assessed for the presence of an enhancing lesion; if an enhancing lesion was detected, its size was measured. RECIST version 1.1 response assessment categories were derived. Pathologic complete response (pCR) was defined as absence of both invasive cancer and ductal carcinoma in situ (DCIS). RESULTS. Of 51 patients, 16 achieved pCR. CEM yielded systematically lower size measurements compared with MRI (mean difference, -0.2 mm for pre-NAT, -0.7 mm for mid-NAT, and -0.3 mm for post-NAT). All post-NAT imaging tests yielded systematically larger size measurements compared with pathology (mean difference, 0.8 mm for CEM, 1.2 mm for MRI, and 1.9 mm for delayed CEM). Of 12 patients with residual DCIS, an enhancing lesion was detected in seven on post-NAT CEM, eight on post-NAT MRI, and nine on post-NAT delayed CEM. Agreement of RECIST response categories between CEM and MRI, expressed as kappa coefficient, was 0.791 at mid-NAT and 0.871 at post-NAT. For detecting pCR by post-NAT imaging, sensitivity and specificity were 81% and 83% for CEM, 100% and 86% for MRI, and 81% and 89% for delayed CEM. Sensitivity was significantly higher for MRI than CEM (p = .001) and delayed CEM (p = .002); remaining comparisons were not significant (p > .05). CONCLUSION. After NAT for breast cancer, CEM and MRI yielded comparable assessments of lesion size (both slightly overestimated vs pathology) and RECIST categories and showed no significant difference in specificity for pCR. MRI had higher sensitivity for pCR. Delayed CEM acquisition may help detect residual DCIS. CLINICAL IMPACT. Although MRI remains the preferred test for NAT response monitoring, the findings support CEM as a useful alternative when MRI is contraindicated or not tolerated.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Bernardi, Vatteroni, Acquaviva, et al. Contrast-Enhanced Mammography Versus MRI in the Evaluation of Neoadjuvant Therapy Response in Patients With Breast Cancer: A Prospective Study. AJR Am J Roentgenol. 2022. PMID: 35731101. doi:10.2214/AJR.22.27756

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。